Chimeric Antigen Receptor T-cell therapy in systemic autoimmune rheumatic diseases: current insights and future prospects
Journal of Rheumatic Diseases · 01.07.2025 · 32 (3) · 154-165
DOI: 10.4078/jrd.2024.0122 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Rheumatic Diseases, online erschienen am 20.01.2025. Verfasst von Bong-Woo Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, K…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Division of Rheumatology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea.
ORCID-Profile: Bong-Woo Lee, Eui-Jong Kwon, Ji Hyeon Ju
Zitieren
APA
Lee, B. W., Kwon, E. J., & Ju, J. H. (2025). Chimeric Antigen Receptor T-cell therapy in systemic autoimmune rheumatic diseases: current insights and future prospects. Journal of Rheumatic Diseases, 32(3), 154-165. https://doi.org/10.4078/jrd.2024.0122
Vancouver
Lee BW, Kwon EJ, Ju JH. Chimeric Antigen Receptor T-cell therapy in systemic autoimmune rheumatic diseases: current insights and future prospects. Journal of Rheumatic Diseases. 2025;32(3):154-165. doi:10.4078/jrd.2024.0122
BibTeX
@article{Lee2025,
author = {Lee, Bong-Woo and Kwon, Eui-Jong and Ju, Ji Hyeon},
title = {Chimeric Antigen Receptor T-cell therapy in systemic autoimmune rheumatic diseases: current insights and future prospects},
journal = {Journal of Rheumatic Diseases},
year = {2025},
volume = {32},
number = {3},
pages = {154--165},
doi = {10.4078/jrd.2024.0122}
}
EUVIMED